Intelligence Feed event · Policy · 2026-09-30

    Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress

    Question

    Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress

    Direct answer

    Gain Therapeutics confirmed it will present long-term open-label clinical findings for rexaceract (GT-02287), an orally administered GCase modulator under development for Parkinson's disease. The presentation will occur during the International Congress of Parkinson's Disease and Movement Disorders in Seoul on October 7, 2026. The milestone serves as an upcoming clinical catalyst for evaluating disease-modifying potential in neurodegenerative indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress”, revision 1, evidence through 2026-09-30. https://marketontology.com/market-events/2026-09-30/gain-therapeutics-to-present-gt-02287-parkinson-data-at-seoul-congress-c5501f

    POLICY
    Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress
    Gain Therapeutics confirmed it will present long-term open-label clinical findings for rexaceract (GT-02287), an orally administered GCase modulator under development for Parkinson's disease. The presentation will occur during the International Congress of Parkinson's Disease and Movement Disorders in Seoul on October 7, 2026. The milestone serves as an upcoming clinical catalyst for evaluating disease-modifying potential in neurodegenerative indications.
    GANX
    Impact
    61
    SEP 30
    SIG
    88%
    GANX
    Gain Therapeutics to Present GT-02287 Parkinson Data at Seoul Congress
    Gain Therapeutics confirmed it will present long-term open-label clinical findings for rexaceract (GT-02287), an orally administered GCase modulator under development for Parkinson's disease. The presentation will occur during the International Congress of Parkinson's Disease and Movement Disorders in Seoul on October 7, 2026. The milestone serves as an upcoming clinical catalyst for evaluating disease-modifying potential in neurodegenerative indications.
    → Clinical data disclosure at an international medical congress drives event-driven option premium and equity re-pricing in GANX ahead of October 7.
    Impact
    Gain Therapeutics confirmed it will present long-term open-label clinical findings for rexaceract (GT-02287), an orally administered GCase modulator under development for Parkinson's disease. The presentation will occur during the International Congress of Parkinson's Disease and Movement Disorders in Seoul on October 7, 2026. The milestone serves as an upcoming clinical catalyst for evaluating disease-modifying potential in neurodegenerative indications.
    Affected
    GANX
    Transmission
    Clinical data disclosure at an international medical congress drives event-driven option premium and equity re-pricing in GANX ahead of October 7.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GANXbiotech clinical catalyst positioning ahead of medical congress presentationUp1-4wGain Therapeutics announced poster presentation of GT-02287 long-term open-label data for Oct 7, 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month